Company intelligence / Profile preview

Dopavision

Ownership: Private
Development stage: Phase 2

Overview

Dopavision’s lead product, MyopiaX®, is a first-in-class digital therapeutic using selective ocular light stimulation to slow the progression of myopia in children. The device non-invasively stimulates retinal dopamine pathways through interactive content on standard digital devices. The MyopiaX‑1 multicenter randomized controlled trial has completed its proof-of-concept phase with topline 6-month data presented at the 19th International Myopia Conference. The therapy was shown to be safe and well-tolerated, with signals of efficacy for slowing myopic progression; full results are pending publication.

Therapeutic areas: Ophthalmology
Modalities: DeviceNon-pharmacological therapyDigital therapeutic (light-based)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

MyopiaX

Phase 2

Indications: Childhood myopia, Progressive myopia

Partnerships

Supported by German Federal Ministry of Education and Research BMBF (“Industrie-in-Klinik” program)

Beyond the preview

Go deeper on Dopavision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dopavision.

Explore the full profile